{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:48:48Z","timestamp":1791568128819,"version":"4.3.4"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1248\/bpb.b19-01080","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T22:11:31Z","timestamp":1601503891000},"page":"1476-1480","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example"],"prefix":"10.1248","volume":"43","author":[{"given":"Rui","family":"Niu","sequence":"first","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"},{"name":"Northwest Women and Children Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Xiang","sequence":"additional","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Guo","sequence":"additional","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianling","family":"Feng","sequence":"additional","affiliation":[{"name":"The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi\u2019an Jiaotong University"},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin. Drug Investig.<\/i>, 37<\/b>, 415\u2013422 (2017).","DOI":"10.1007\/s40261-017-0503-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J. Pharmacol. Pharmacother.<\/i>, 3<\/b>, 228\u2013232 (2012).","DOI":"10.4103\/0976-500X.99417"},{"key":"3","unstructured":"3) Alves C, Marques FB, Macedo AF. Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier. Eur. J. Clin. Pharmacol.<\/i>, 70<\/b>, 745\u2013756 (2014)."},{"key":"4","unstructured":"4) Alves C. The role of meta-analysis in pharmacovigilance: how best to combine different sources of evidence about harms? Universidade de Coimbra (2015)."},{"key":"5","unstructured":"5) Tuccori M, Montagnani S, Capogrossosansone A, Mantarro S, Antonioli L, Fornai M, Blandizzi C. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev. Clin. Pharmacol.<\/i>, 8<\/b>, 61\u201375 (2015)."},{"key":"6","unstructured":"6) B\u00e9n\u00e9 J, Rousselin C, Bagheri H, Vial T, Gautier S, Lambert M. Non-hemorrhagic joint disorders and vitamin K antagonists: an under recognized adverse drug reaction? Fundam. Clin. Pharmacol.<\/i>, 32<\/b>, 663\u2013668 (2018)."},{"key":"7","unstructured":"7) Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br. J. Clin. Pharmacol.<\/i>, 83<\/b>, 1532\u20131543 (2017)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs.<\/i> S-1 as first-line treatment in elderly patients with Metastatic or recurrent unresectable gastric cancer. Br. J. Cancer<\/i>, 99<\/b>, 584\u2013590 (2008).","DOI":"10.1038\/sj.bjc.6604536"},{"key":"9","unstructured":"9) Zhang HY, Sun LZ. The clinical study of domestic compound tegafur capsule first-line therapy for patients with elderly advanced gastric cancer. Medical Innovation of China<\/i>, 29<\/b>, 94\u201396 (2010)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br. J. Clin. Pharmacol.<\/i>, 57<\/b>, 616\u2013621 (2004).","DOI":"10.1111\/j.0306-5251.2003.02055.x"},{"key":"11","unstructured":"11) Bouch\u00e9 O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial. Ann. Oncol.<\/i>, 16<\/b>, 1488\u20131497 (2005)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cullinan SA, Moertel CG, Wieand HS, O\u2019Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK. Controlled evaluation of three drug combination regimens versus<\/i> fluorouracil alone for the therapy of advanced gastric cancer. J. Clin. Oncol.<\/i>, 12<\/b>, 412\u2013416 (1994).","DOI":"10.1200\/JCO.1994.12.2.412"},{"key":"13","unstructured":"13) Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A. Fluorouracil versus<\/i> combination of irinotecan plus cisplatin versus<\/i> S-1 in Metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol.<\/i>, 10<\/b>, 1063\u20131069 (2009)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Coombes RC, Chilvers CED, Amadori D, Medi F, Fountzilas G, Rauschecker H, Vassilopoulos P, Ferreira EP, Vannozzi G, Bliss JM, Woods E, Wils J. Randomised trial of epirubicin versus<\/i> fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann. Oncol.<\/i>, 5<\/b>, 33\u201336 (1994).","DOI":"10.1093\/oxfordjournals.annonc.a058686"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A, Sawaki A, Nishisaki H, Amagai K, Suzuki Y. Randomized phase III study of 5-fluorouracil continuous infusion vs.<\/i> sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis. Jpn. J. Clin. Oncol.<\/i>, 43<\/b>, 972\u2013980 (2013).","DOI":"10.1093\/jjco\/hyt114"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized phase III trial of fluorouracil alone versus<\/i> fluorouracil plus cisplatin versus<\/i> uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer. The Japan Clinical Oncology Group Study. J. Clin. Oncol.<\/i>, 21<\/b>, 54\u201359 (2003).","DOI":"10.1200\/JCO.2003.04.130"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chlebowski RT, Weiner JM, Silverberg I, Glass A, Bateman JR. Cyclophosphamide plus FU versus<\/i> FU alone in advanced gastric carcinoma. Oncology<\/i>, 42<\/b>, 141\u2013143 (1985).","DOI":"10.1159\/000226020"},{"key":"18","unstructured":"18) Lutz MP, Wilke H, Wagener DJT, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, Balleisen L, Joossens E, Jansen RL, Debois M, Bethe U, Praet M, Wils J, Van Cutsem E. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU\/FA), or HD-FU\/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol.<\/i>, 25<\/b>, 2580\u20132585 (2007)."},{"key":"19","unstructured":"19) Yoshitaka Y, Itsuo M, Makoto O. A random controlled trial with methotrexate (MTX), 5-fluorouracil (FU) and pirarubicin (THP) vs.<\/i> FU alone in advanced or recurrent gastric carcinoma. Jpn. J. Cancer Chemother.<\/i>, 25<\/b>, 1543\u20131548 (1988)."},{"key":"20","unstructured":"20) Prada-Ramallal G, Takkouche B, Figueiras A. Summarising the evidence for drug safety: a methodological discussion of different meta-analysis approaches. Drug Saf.<\/i>, 40<\/b>, 547\u2013558 (2017)."},{"key":"21","unstructured":"21) Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf.<\/i>, 38<\/b>, 437\u2013453 (2015)."},{"key":"22","unstructured":"22) Jiafu J, Zhemin L, Tang X. Strategies of diagnosis and treatment of gastric cancer in the era of big data and precision medicine. Chinese Journal of Practical Surgery<\/i>, 35<\/b>, 1033\u20131036 (2015)."},{"key":"23","unstructured":"23) Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLOS ONE<\/i>, 11<\/b>, e0160221 (2016)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions\u2014systematic literature survey of follow-up. BMJ<\/i>, 332<\/b>, 335\u2013339 (2006).","DOI":"10.1136\/bmj.38701.399942.63"},{"key":"25","unstructured":"25) Motola D, Donati M, Biagi C, Calamelli E, Cipriani F, Melis M, Monaco L, Vaccheri A, Ricci G. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol. Drug Saf.<\/i>, 26<\/b>, 1164\u20131171 (2017)."},{"key":"26","unstructured":"26) Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med.<\/i>, 8<\/b>, e1001026 (2011)."},{"key":"27","unstructured":"27) Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia\u2013Romagna region). Eur. J. Clin. Pharmacol.<\/i>, 69<\/b>, 237\u2013244 (2013)."},{"key":"28","unstructured":"28) Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S. The drugs that mostly frequently induce acute kidney injury: a case\u2014noncase study of a pharmacovigilance database. Br. J. Clin. Pharmacol.<\/i>, 83<\/b>, 1341\u20131349 (2017)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Huang L, Guo T, Zalkikar JN, Tiwari RC. A review of statistical methods for safety surveillance. Ther. Innov. Regul. Sci.<\/i>, 48<\/b>, 98\u2013108 (2014).","DOI":"10.1177\/2168479013514236"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf.<\/i>, 37<\/b>, 581\u2013596 (2014).","DOI":"10.1007\/s40264-014-0194-3"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/10\/43_b19-01080\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T03:11:41Z","timestamp":1601694701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/10\/43_b19-01080\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-01080","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}